FDA.reportPublic FDA data

atezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT per 15 ML Injection

RxCUI
2693892
RxNorm name
atezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT per 15 ML Injection
Display name
atezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT per 15 ML Injection
Full name
atezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT per 15 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:12

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761347Tecentriq Hybrezaatezolizumab and hyaluronidase-tqjs351(a)Rx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Tecentriq HybrezaATEZOLIZUMAB AND HYALURONIDASE-TQJSGenentech, Inc.a617b089-ce66-464b-987b-b45d029b4d6f2026-05-20Warnings, Adverse reactionsExact identifier
rxcui: 2693892

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a617b089-ce66-464b-987b-b45d029b4d6fatezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT in 15 ML Injection [PSN] · 15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection [SCD] · atezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT per 15 ML Injection [SY]37These highlights do not include all the information needed to use TECENTRIQ HYBREZA safely and effectively. See full prescribing information for TECENTRIQ HYBREZA. TECENTRIQ HYBREZA ® (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use Initial U.S. Approval: 202420260520